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Introduction: Molecular markers that predict responses to particular therapies are invaluable for optimization of
patient treatment. The TRYPHAENA study showed that pertuzumab and trastuzumab with chemotherapy was an
efficacious and tolerable combination for patients with human epidermal growth factor receptor 2 (HER2)-positive
breast cancer in the neoadjuvant setting. We analyzed whether particular biomarkers correlated with the responses
observed and therefore may predict outcomes in patients given pertuzumab plus trastuzumab.
Methods: We describe the analysis of a panel of biomarkers including HER2, human epidermal growth factor receptor 3
(HER3), epidermal growth factor receptor (EGFR), phosphatase and tensin homolog (PTEN), and phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) by qRT-PCR, immunohistochemistry (IHC), fluorescence in situ
hybridization (FISH), enzyme-linked immunosorbent assay (ELISA), and PCR-based mutational analyses as appropriate.
For each marker analyzed, patients were categorized into ‘low’ (generally below median) or ‘high’ (generally above
median) subgroups at baseline and post-treatment.
Results: Correlation of marker subgroups with the achievement of a pathological complete response (pCR) (ypT0/is)
was analyzed. HER2 protein and mRNA expression levels were associated with pCR rate in two of the three study arms
and the pooled analyses. Correlations of biomarker status with pCR occurred in one individual arm only and the pooled
analyses with EGFR and PTEN; however, interpretation of these results is limited by a strong imbalance in patient numbers
between the high and low subgroups and inconsistency between arms. We also found no association between
expression levels of TOP2A and pCR rate in either the anthracycline-containing or free arms of TRYPHAENA.
Conclusions: According to these analyses, and in line with other analyses of pertuzumab and trastuzumab in the
neoadjuvant setting, we conclude that HER2 expression remains the only marker suitable for patient selection for this
regimen at present.
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Human epidermal growth factor receptor 2 (HER2) over-
expression or amplification has previously been identified
as a poor prognostic factor in breast cancer patients [1,2].
Novel HER2-targeting agents have, however, improved
outcomes in patients with HER2-positive breast cancer
to a comparable level to those in patients with HER2-
negative disease [3], if not greater relative to certain
subtypes (for example, basal-like breast cancers).
HER2-targeted therapies are the mainstay of treatment
of HER2-overexpressing or gene-amplified metastatic
breast cancer [4]. The addition of trastuzumab (Herceptin™,
Roche, Switzerland) to a taxane improved overall survival
in patients with HER2-overexpressing metastatic breast
cancer [5]. The CLEOPATRA study showed that the
addition of pertuzumab (PERJETA™, Roche, Switzerland)
to trastuzumab plus taxane further increased progression-
free survival (PFS) [6] as well as significantly improving
overall survival (OS) when compared with trastuzumab
plus a taxane alone [7]. Like trastuzumab, pertuzumab is a
HER2-targeted humanized monoclonal antibody; however,
it binds to a unique epitope in the dimerization domain
and has a complementary mode of action to trastuzumab
[8,9]. Thus, HER2 is currently the only validated bio-
marker for treatment with trastuzumab or pertuzumab
in metastatic breast cancer (MBC) [10,11].
In addition to HER2, a number of components from
the HER signaling pathways and other signaling pathways
have previously been suggested to predict responsiveness
(or lack of ) to HER-targeted agents, including phos-
phatase and tensin homolog (PTEN), [12-14], Akt [15],
p95HER2 [16], c-Myc [17], and various growth factors
and their receptors such as insulin-like growth factor
(IGF-1) [18]. These studies concluded that expression
levels of these pathway components had an impact on
outcomes and often correlated with resistance to tras-
tuzumab. Conflicting clinical data exist on the potential
predictive value of serum extracellular domain (ECD)
HER2 levels for the outcome of treatment with HER2-
targeted agents [19]. Fornier et al. [19] showed that (serum/
shed) human epidermal growth factor receptor 2 (sHER2)
levels correlated with response rate; however, Lennon
et al. [20] saw no clear relationship between baseline
sHER2 levels and tumor response. Additional data are
therefore required to clarify the role of sHER2 as a
marker of response.
The TRYPHAENA study, a randomized, multicenter,
multinational phase II study, showed that pertuzumab in
combination with trastuzumab given either concomitantly
or sequentially with standard anthracycline-based chemo-
therapy or concomitantly with a non-anthracycline-based
chemotherapy regimen, is well tolerated and efficacious as
neoadjuvant therapy for patients with locally advanced,
inflammatory, or early stage HER2-positive breast cancer[21]. An exploratory analysis of biomarkers to determine
whether biomarker expression correlated with response
to trastuzumab- plus pertuzumab-based regimens was
carried out. The biomarkers investigated included markers
of the expression and activation of HER-family recep-
tors and related receptor tyrosine kinases, ligands, and
downstream signaling components [22]. The biomarkers
measured were HER2 (protein and mRNA), HER3 (pro-
tein and mRNA in tumor tissue), epidermal growth factor
receptor (EGFR) (protein and mRNA in tumor tissue),
amphiregulin (serum protein and mRNA), betacellulin
(mRNA), IGF-1R (protein), PTEN (protein), transforming
growth factor alpha (TGFα) (serum protein), epidermal
growth factor (EGF) (serum protein), serum HER2/shed
HER2 (sHER2), amplifications of c-Myc or topoisomerase
2A (TOP2A), and mutations in phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha (PIK3CA).
Here we report the results of the biomarker analysis.Materials and methods
Study design
The details of the trial design and patient population
have been previously reported [21]. Briefly, 225 patients
were recruited to the TRYPHAENA study from 44 centers
in 19 countries; 73 patients were randomized 1:1:1 to
Arm A (six cycles of pertuzumab plus trastuzumab,
with 5-fluorouracil/epirubicin/cyclophosphamide (FEC)
for cycles one to three and docetaxel for cycles four to
six), 75 to Arm B (FEC for cycles one to three followed by
pertuzumab plus trastuzumab with docetaxel for cycles
four to six), and 77 to Arm C (six cycles of pertuzumab plus
trastuzumab with docetaxel and carboplatin) (Figure 1).
The study was conducted in full accordance with the guide-
lines for Good Clinical Practice and the Declaration of
Helsinki. Written informed consent was obtained from
each participant. Approval for the protocol and for any
modifications was obtained from independent ethics
committees (committees are listed in Additional file 1).
Baseline demographics were generally well balanced across
arms (Table S1 in Additional file 2).Biomarker assessments
Tumor samples (either core biopsies or incisional biopsies)
were taken from all patients at baseline. Biopsies of the
primary tumor were collected for central confirmation
of HER2 status and assessment of candidate markers
in tumor tissue. Tumor samples from patients with
residual disease were also collected at definitive surgery
(Figure 1).
Serum samples (4.9 mL whole blood per sample) for
biomarker assessment were collected at baseline and at
the time of definitive surgery (Figure 1).
Figure 1 The TRYPHAENA study design. (Biomarker assessments are indicated by arrows).
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Immunohistochemistry (IHC)
IHC for HER2, HER3, IGF-1R, and PTEN was performed
(by Targos Molecular Pathology GmbH, Germany) on 4
μm tumor tissue sections. HER2 levels were assessed
using the Ventana Pathway 4B5™ kit (Ventana Medical
Systems, USA) as per the manufacturer’s instructions.
All other proteins were detected using commercially
available monoclonal antibodies (CONFIRM™ anti-IGF-1R
(G11) rabbit monoclonal primary antibody, (Ventana Med-
ical Systems, USA); anti-human EGFR clone 3C6, (Ventana
Medical Systems, USA); mouse anti-human HER3 clone
DAK-H3-1C, code M7297, (Dako, Denmark); 138G6
PTEN, (Cell Signaling, USA). Protein expression was evalu-
ated semiquantitatively by several pathologists using
multicategorical, exploratory IHC scoring. Compulsory
assessment for pathologists participating in the study en-
sured high levels of inter- and intra-reader concordance.
Inter-reader concordance at the central laboratory is
>99% for HER2 with only 0.76% samples re-scored after
reassessment. Local preselection based on HER2 status
was carried out and HER2 results were confirmed by thecentral laboratory prior to patient randomization. For
each biomarker assessed by IHC, a modified H-score
[23] was derived by classifying the intensity of staining
according to three categories (1+, 2+, 3+) and assessing
the percentage of tumor cells within each staining inten-
sity (P1, P2, P3, respectively). A modified H-score was
calculated as follows: 1 was added to each staining in-
tensity (1+, 2+, and 3+) and then multiplied by the cor-
responding percentage of tumor cells (P1, P2, and P3).
The percentage of cells stained with an intensity of 0
was used only as a quality-control check. The modified
H-score was therefore defined as:
Modified H‐score ¼ 1þ 1ð Þ  P1 þ 2þ 1ð Þ  P2
þ 3þ 1ð Þ  P3:
This score has a maximum value of 400. In cases
where no staining was observed on the entire tissue
section a score of 0 was given. A minimum of 10 viable
tumor cells were counted. For each sample, staining
intensities and patterns per cell compartment (that is,
membrane, cytoplasm, nucleus) were assessed separately.
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score) was calculated for those cell compartments for
which specific staining was identified and a biologic
rationale for the subcellular location of the respective
marker existed (for example, for PTEN, nuclear staining is
reported to contribute specifically to its tumor suppressor
function).
Quantitative real time-polymerase chain reaction (qRT-PCR)
To assess mRNA expression of HER2, HER3, EGFR,
amphiregulin, and betacellulin, 200 ng RNA was isolated
from tumor tissue sections. qRT-PCR was performed,
on the LightCycler™ 2.0 instrument (Roche Diagnostics,
Switzerland), using the LC pertuzumab RT-PCR kit, ac-
cording to in-house (Targos Molecular Pathology GmbH,
Germany) specifications.
Mutational assay
The mutational status of PIK3CA was assessed at Transla-
tional Research Sciences (TRS), Roche, Switzerland, using
a TaqMan-based assay (Roche Diagnostics, Switzerland)
that detects mutations at four hotspots in exons 7, 9, and
20. The eight mutations detected are: 420R, 542K, 545K,
545A, 545G, 1047R, 1047L, and 1047Y.
Fluorescence in situ hybridization (FISH)
FISH analysis of HER2, c-Myc, and TOP2A gene amplifica-
tion status was carried out using commercially available
kits and probes (HER2 FISH pharmDx™ Kit, MYC/CEN-8
FISH Probe Kit and TOP2A FISH pharmDx™ Kit respect-
ively, all from Dako, Denmark).
Immunoassays
Immunoassays based on an enzyme-linked immmuno-
sorbent assay (ELISA) principle were performed using
the immunological multi-parameter chip technique
(IMPACT) (Roche, Switzerland). Serum samples were
analyzed in duplicate on the CHIP R-ONC 1.02 chip
for determination of amphiregulin, EGF, TGFα, and
sHER2 (HER2 ECD). The average concentration of
two replicates was reported for each sample. Samples
below the level of quantification were excluded from
the statistical analyses. (Similar results were obtained
if these samples were instead coded as 0).
All assays were carried out using the manufacturer’s
instructions where available and were otherwise fully
validated ‘in-house’ to ensure high-quality, sensitive read-
outs and robust reproducibility of the assays. Additional
methods information is included in Additional file 3.
Statistical and analytical methods
The basic statistics and interdependencies of the different
markers were investigated descriptively using summary
statistics, scatter plots, and box plots. For correlativeanalyses the patient population was divided in two
subgroups per marker, a ‘marker high’ and a ‘marker
low’ subgroup. The cut point which defined the two
subgroups was set as the median for each marker, with
the exception of the following: c-Myc, a c-Myc:chromo-
some 8 signal ratio of ≥2.0 was defined as ‘high’ as this
signifies gene amplification; TOP2A, a TOP2A:chromo-
some 17 signal ratio of ≥2.0 was defined as ‘high’; PIK3CA
mutations, groups were defined based on the presence or
absence of any mutation (yes/mut versus no/WT), ‘WT’
being assigned only to samples in which all reactions gave
a valid result for ‘No mutation’, whereas if one or more
reactions failed, that sample was classified as ‘NA’. The
rationale for using the median as the cut point definition
(for most markers) is that unlike the mean, the median
is largely at the highest density (mode); therefore, in an
exploratory setting, the median serves the purpose of
identifying high and low subgroups until the ‘true’ cut
point is known. The median cut point is also the least
sensitive to abnormalities in data, such as when the
data are skewed from normal distribution. As the study
design does not include a control arm (that is, without
pertuzumab administration), it was not possible to identify
markers of response to pertuzumab. Therefore, within-arm
analyses comparing patients with a pathologic complete
response (pCR) (ypT0/is) with patients not achieving a pCR
were performed for each biomarker studied. By pooling
treatment arms, the overall study population was also
assessed. Pooling the data from all three arms ensured
sufficient data were available, particularly when considering
the more stringent definitions of pCR; however, the ana-
lyses presented here are considered exploratory and P
values should not be used to draw definitive conclusions.
Results
Baseline biomarker levels
The proportion of patients with valid biomarker mea-
surements ranged from 48% to 97% for the biomarkers
analyzed with the exception of HER2 membrane by
IHC, which was collected for 100% of patients (as it was
required for study inclusion). The variability in data
availability was more apparent for biomarkers measured
in tissue (48% to 93% (excluding HER2)) than in serum
samples (90% to 97%) due to technical failure, mainly
attributed to suboptimal tissue quality or limited avail-
ability of tumor tissue.
At baseline, the expression levels of the markers ana-
lyzed were well balanced across the three treatment
arms with the exception of median HER3 protein and
mRNA levels, which were lower in Arm B than in Arms
A and C (Table S2 in Additional file 2). Since analyses
were generally performed within arms rather than
between arms, however, this does not impact overall
conclusions.
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had an H-score at exactly the median cut point of 400
or 200, respectively, resulting in unequal distribution
between the ‘high’ and ‘low’ subgroups as only a few
patients were categorized as ‘low’.
Although betacellulin and amphiregulin mRNA levels
were above the specified limit of detection, the quantities
detected by qRT-PCR were very small in the majority of
patients. Therefore, the signal strength for the mRNA
for these markers was too weak to allow for meaningful
data interpretation particularly in the case of betacellulin.
Hence betacellulin was not included in the correlative
analyses as observed differences were still within the
variance of the assay, while data for amphiregulin that
are shown have to be interpreted with caution.
The EGFR protein expression levels as detected by IHC
were also generally low, with no expression detected in
the majority of cases, making data interpretation difficult.
Correlation of baseline biomarker levels with clinical
outcome (pCR, ypT0/is)
pCR (ypT0/is (no evidence of invasive tumor residues in
the breast)) rates were compared between patients in the
‘high’ or ‘yes’ subgroups for each biomarker versus the
‘low’ or ‘no’ subgroups, for all treatment arms separately
or pooled. For the pooled analyses the chi-squared test
was used to explore whether differences observed were
statistically significant when adjusted for estrogen receptor
(ER) status (Table 1). Adjustment for ER status was
important to rule out potential bias in data interpret-
ation introduced by ER status since pCR rates were
considerably lower in patients with ER-positive disease
versus those in the ER-negative group [21]. Figure 2
shows the unadjusted data per arm.
The population enrolled in the TRYPHAENA study
was centrally selected for HER2 overexpression and in
general showed very high HER2 expression levels. Almost
all patients reached the maximum level as measured by
the modified H-score with a very narrow dynamic range
in general, most prominent in Arm B (Figure 3A). This
fact has to be taken into account particularly when
interpreting HER2-related data. Of the markers analyzed,
HER2 levels (protein and mRNA) showed an association
with pCR rates when data from all arms were pooled.
With almost no numerical difference in the HER2 protein
levels between those above and below the median,
comparison of truly different patient populations with
regard to HER2 expression is not possible. In Arm B
such association was not observed for HER2 protein
or for HER2 mRNA levels but the comparison of the
two unevenly sized groups (60 (high) versus 15 (low))
makes accurate interpretation difficult. When comparing
baseline HER2 expression in patients who later went on to
achieve a pCR to expression in those who did not, levelsof expression were generally more variable in the group of
patients who did not go on to achieve a pCR (Figure 3B).
There was, however, a substantial overlap in expression
levels between the two groups, which did not allow
identification of a meaningful cutoff point to discriminate
between the responder and nonresponder groups.
EGFR membrane and PTEN cytoplasm H-scores showed
significant correlations with pCR rates in Arm C only
(the anthracycline-free arm). When arms were pooled the
correlation was significant, as described by chi-squared
test (P = 0.0157). (High EGFR membrane expression
correlated with lower pCR rates, whereas the opposite
was true for PTEN cytoplasm scores). However, these
results were limited by the inconsistency observed
between arms and by there being too few patients in
the ‘low’ subgroup for PTEN (six to nine per arm) to
allow any conclusions to be drawn. Complete absence
of PTEN, which is biologically the most meaningful
cutoff was only observed in five patients therefore not
allowing correlative analyses. Similarly, for EGFR, protein
expression levels were generally very low or absent in the
majority of cases; therefore, the number of patients in
the ‘high’ group (10 to 15 per arm) was too low to allow
reliable analysis and correlations were not consistent
across arms. For IGF-1R membrane H-score when adjusted
for estrogen receptor status, there was no significant
difference in pCR rate between patients in the high and
low subgroups. TOP2A amplification status did not appear
to be associated with a differential benefit in patients
receiving anthracycline treatment. In patients carrying
a PIK3CA mutation, a numerically lower pCR rate was
observed compared to patients whose tumors expressed
wild-type PIK3CA. This was seen in all treatment arms
but did not reach statistical significance. In a per-exon
analysis, no difference was seen between mutations in exon
9 and mutations in exon 20 regarding their association
with pCR rates. No exon 7 mutations were detected in
the TRYPHAENA population (Table 2).
Correlation of baseline biomarker levels with pCR by
different definitions (ypT0/is, ypT0, ypT0/is ypN0,
ypT0 ypN0)
For the majority of biomarkers, any correlation or lack
of correlation with pCR remained consistent regardless
of the pCR definition applied (ypT0/is, no evidence of
invasive tumor but noninvasive tumor may be present
(that is, carcinoma in situ); ypT0, no evidence of invasive
tumor; ypT0/is ypN0, no evidence of invasive tumor, no
regional lymph node metastasis (noninvasive tumor may
be present); ypT0 ypN0, no invasive or noninvasive tumor,
no regional lymph node metastasis). (Data not shown.)
The only exceptions observed were: PTEN H-score in
cytoplasm was not associated with pCR except by the
ypT0 ypN0 definition in Arm C; no significant association
Table 1 The relationship between biomarker levels and whether a pathologic complete response (pCR) was achieved,
adjusted for estrogen receptor status (all arms pooled)
Biomarker* Patients achieving a pCR in the
‘high’ or ‘yes’ subgroup, n/N (%)
Patients achieving a pCR in the
‘low’ or ‘no’ subgroup, n/N (%)
P value (chi-squared test)
HER2 membrane 115/159 (72.3) 24/66 (36.4) 0.00002
HER3 membrane 32/58 (55.2) 38/54 (70.4) 0.32864
IGF-1R membrane 27/57 (47.4) 44/56 (78.6) 0.05313
EGFR membrane 21/36 (58.3) 48/73 (65.8) 0.01037
PTEN cytoplasmic 59/92 (64.1) 11/21 (52.4) 0.04968
PTEN nuclear 39/60 (65.0) 31/53 (58.5) 0.22086
EGFR mRNA 65/98 (66.3) 60/98 (61.2) 0.65169
HER2 mRNA 78/106 (73.6) 53/104 (51.0) 0.00060
HER3 mRNA 60/105 (57.1) 71/105 (67.6) 0.89283
Amphiregulin mRNA 55/95 (57.9) 66/95 (69.5) 0.42068
TOP2A 35/62 (56.5) 83/130 (63.9) 0.57728
c-Myc 40/61 (65.6) 66/106 (62.3) 0.52483
Amphiregulin 68/102 (66.7) 62/101 (61.4) 0.29743
EGF 65/102 (63.7) 65/101 (64.4) 0.83132
sHER2 68/102 (66.7) 62/101 (61.4) 0.89167
TGFα 60/102 (58.8) 70/101 (69.3) 0.16475
PIK3CA mutation 19/39 (48.7) 81/126 (64.3) 0.17160
*All biomarkers assessed by IHC are represented by H-scores. EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HER, human epidermal
growth factor receptor; IGF-1R, insulin-like growth factor 1 receptor; PIK3CA, phosphoinositide-3-kinase, catalytic alpha polypeptide; PTEN, phosphatase and tensin
homolog; sHER2, serum HER2; TGFα, transforming growth factor alpha; TOP2A, topoisomerase 2 alpha.
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for the ypT0 and ypT0 ypN0 definitions; HER2:HER3
levels were significant in Arm C for ypT0 and ypT0 ypN0
definitions; the incidence of PIK3CA mutations showed
no correlation with pCR overall for the ypT0/is ypN0
definition unlike the other definitions and if the data
were not pooled then a significant association was
observed only in Arm B with the ypT0 ypN0 definition.
The relationship between pCR and biomarker changes
following treatment
Matched pair analyses were carried out to evaluate the
effect of treatment on biomarker levels in both serum
and tissue samples. In serum samples, sHER2 and TGFα
levels substantially decreased during treatment, whereas
both amphiregulin and EGF levels remained similar
irrespective of treatment (Figure 4). When changes in
biomarker levels occurred between baseline and time of
surgery, these were similar regardless of whether patients
had a pCR or not. Any changes observed were consistent
across all treatment arms.
Analyses of tissue samples revealed that PTEN nuclear
H-score and HER2 mRNA levels substantially decreased
between baseline and surgery. EGFR mRNA levels were
observed to increase significantly during the same period,
although overall levels were very low (Figure 5). The
median HER2 membrane H-score was somewhat reducedat time of surgery, but this observation was not statisti-
cally significant and in the majority of cases did not
impact the overall IHC scoring. In nine patients, this led
to a change in HER2 status (that is, HER2-positive to
HER2-negative disease) although this does not necessarily
equate to a complete loss of HER2 expression. Other
markers remained unchanged. As these tissue analyses are
only possible in patients not achieving pCR, no judgment
can be made regarding whether those changes are charac-
teristic for sensitivity to treatment.
Correlation of biomarker levels with tumor size
In addition to analyzing association of biomarkers with
pCR as an endpoint, the correlation of biomarkers with
tumor size (degree of tumor shrinkage) was also measured
as an alternative endpoint. No correlations were found
between the level or presence of any biomarker and tumor
shrinkage as a result of treatment (data not shown).
Discussion
In the TRYPHAENA study, a range of biomarkers and
their association with pCR were assessed. Although the
biomarker analysis methods used at the time of this
investigation were considered ‘state of the art’, newer
methods such as quantitative IHC or immunofluorescence
techniques have since come into common use. The use of
these techniques (where appropriate) may be of value to
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Figure 2 Analysis by treatment arm of the relationship between biomarkers and pathologic complete response (pCR), adjusted for
estrogen receptor status and breast cancer type (operable, locally advanced or inflammatory breast cancer). Forest plots represent the
pCR rate (circle) with 95% confidence limits (line). The high or low categorization indicates whether biomarker levels were above or below the
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quantification possible.
According to our analyses, no subpopulation within
the patients with HER2-positive disease in TRYPHAENA
could be identified who might derive the greatest benefit
from pertuzumab-containing regimens or who should
not be treated with pertuzumab, since patients in all
arms received pertuzumab therapy. In TRYPHAENA,
HER2 expression at both the protein and mRNA levels
were the only biomarkers associated with pCR rate.
This correlation was not observed in Arm B, which
may be attributed to the fact that in Arm B the treat-
ment duration was shorter, with only three cycles of
HER2-targeted therapy compared with six cycles in the
other two treatment arms. Applying the current scoring
criteria, HER2 expression remains the only marker suit-
able for patient selection at present.
It should be taken into account that the patients en-
rolled in TRYPHAENA showed relatively high HER2
protein expression levels, with a very narrow dynamic
range and little numerical difference in the protein levels
between those above and below the median. As themajority of tumors expressed HER2 at the maximum
detectable level of H-score 400, two unequally sized
groups (70% versus 30% of the patients) were compared
as the median of 400 was used as cut point. Therefore,
the HER2 expression levels at the cut point that were
identified in this population to be associated with pCR
cannot likely define a clinically meaningful and biologic-
ally distinct subpopulation.
When data were pooled for all three arms, statistically
significant correlations of biomarker status with pCR
also occurred with EGFR (membrane H-score) and PTEN
(cytoplasm H-score); however, there were only a small
number of patients in the PTEN ‘low’ subgroup (owing to
the majority of patients falling exactly on the median cut
point) and in the EGFR ‘high’ subgroup (owing to low
expression levels across the population), which limits
the interpretation of these results. In addition, significant
association of EGFR and PTEN expression with pCR
status was observed in Arm C but not Arms A and B,
although there is no biologic rationale as to why an
association would be attributable to a different chemo-
therapy backbone or sequence thereof rather than
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Figure 3 The relationship between human epidermal growth
factor receptor 2 (HER2) expression and efficacy. (A) Baseline HER2
membrane H-score by treatment arm (Arm A n = 73, Arm B n = 75,
and Arm C n = 77); (B) Box plot to describe the relationship between
baseline HER2 membrane H-score and achievement of pathologic
complete response by treatment arm (in the box plot, the horizontal
line represents the median value, the diamond represents the mean,
the upper and lower bounds of the box represent the 75th and 25th
quartiles, respectively, and whiskers represent 95% confidence limits).
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fore be somewhat artificial or biased due to the small
numbers of patients and multiple analyses performed.
Future trials with larger samples sizes are needed to explore
the robustness of the signal.
Previous analyses have noted that TOP2A amplification
in HER2-positive patients was a predictor of extended PFSTable 2 PIK3CA mutation-dependent responsiveness to
pertuzumab treatment (all arms pooled)
PIK3CA exons Number of patients achieving a pathological
complete response (pCR) per-exon mutation/total
number of patients with a mutation in that exon
(population pCR rate 139/225 (62%))
Exon 7 0/0
Exon 9 5/11
Exon 20 14/28and disease-free survival (DFS) for patients who received
anthracycline therapy with or without trastuzumab [24].
In TRYPHAENA, no association was identified between
expression levels of TOP2A and pCR rate in either the
anthracycline-containing (Arms A and B) or anthracycline-
free (Arm C) arms. This might be due to the additional
administration of pertuzumab in TRYPHAENA, unlike in
the study by Press et al. [24]. As the addition of pertuzu-
mab significantly increases pCR rate [10] any additional
anthracycline-specific benefit might be masked, or perhaps
a lack of efficacy of anthracyclines in some patients might
be overcome by treatment with two anti-HER2-targeted
antibodies. Alternatively, the difference may be due to
the different outcome measures used or to our limited
sample size. Press et al. [24] considered the association
of TOP2A amplification and improved PFS or DFS with
anthracycline-containing therapy, that is, looking at long-
term benefit, whereas TRYPHAENA explored the rela-
tionship between TOP2A amplification and pCR rate with
anthracycline-containing treatment and analyzes tumor
response as a shorter-term response measure.
Mutations in exon 9 of PIK3CA have been linked to a
lack of sensitivity, that is, reduced pCR rate in patients
receiving HER2-targeted therapy with trastuzumab,
pertuzumab, or both [10]. In TRYPHAENA, generally,
numerically lower pCR rates were observed in patients
with tumors carrying any PIK3CA mutation tested for,
although this did not reach a statistically significant level.
As this was consistent across arms and in the absence
of a control arm, it was not possible to correlate this to
HER2-targeted treatments. No correlation between specific
PIK3CA mutations and pCR was observed in TRYPHA
ENA, though the sample sizes in TRYPHAENA would
have limited the power to detect specific correlations.
A number of different pCR definitions were applied
during data analysis and, in general, it was found that
the results were consistent regardless of the definition
used. The small differences in pCR rates according to
different definitions highlight the need for consistency of
pCR definition use across studies to allow meaningful
comparison. pCR defined by ypT0 ypN0 has recently been
associated with the most favorable outcomes following
neoadjuvant chemotherapy compared with less stringent
pCR definitions [25].
Although changes in serum biomarker levels were
observed between baseline and surgery, these were not
associated with pCR and therefore could not be defined
as markers of response. Some changes in biomarker levels
in tumor tissue from baseline to surgery were observed,
but these cannot be correlated to outcome owing to the
lack of tissue availability from patients achieving pCR. The
observed reduction in HER2 mRNA may indicate early
changes that are not yet reflected in HER2 protein levels.
This could be due to the short treatment duration or may
A B
C D
10
0
20
Baseline BaselineSurgery Surgery
Se
ru
m
 T
G
Fα
 [p
g/
m
L]
Serum TGFα
30
800
400
RD pCR
6
4
2
Se
ru
m
 A
m
ph
ire
gu
lin
 [p
g/
m
L]
Serum Amphiregulin
8
10
50
100
RD pCR
Baseline Surgery Baseline Surgery
750
500
250
0
Se
ru
m
 E
G
F 
[p
g/
m
L]
Serum EGF
1000
1250
Baseline BaselineSurgery Surgery
RD pCR
15
10
5
Se
ru
m
 s
H
ER
2 
[n
g/
m
L]
Serum sHER2
25
100
200
20
Baseline BaselineSurgery Surgery
300
RD pCR
Figure 4 Analysis of serum biomarker levels at baseline and at surgery, by pathologic complete response status. (A) sHER2, (B)
amphiregullin, (C) EGF, (D) TGFα. (n = 112 for pCR (responders) and n = 56 for residual disease (RD) (nonresponders)) (in the box plot, the
horizontal line represents the median value, the diamond represents the mean, the upper and lower bounds of the box represent the 75th and
25th quartiles, respectively, and whiskers represent 95% confidence limits). EGF, epidermal growth factor; pCR, pathological complete response; (s)
HER2, (serum/shed) human epidermal growth factor receptor 2; TGFα, transforming growth factor alpha.
Schneeweiss et al. Breast Cancer Research 2014, 16:R73 Page 9 of 12
http://breast-cancer-research.com/content/16/4/R73indicate that the protein remains stable despite changes in
mRNA levels. No conclusion can be drawn on whether
such changes predict for nonresponse to pertuzumab-
containing regimens.
In addition, we considered tumor size as an alternative
clinically meaningful endpoint to pCR for correlative
analyses with biomarkers. However, no biomarker tested
was found to correlate with tumor shrinkage.Conclusions
The results from the TRYPHAENA study, consistent with
findings from the NeoSphere [10] and CLEOPATRA [11]
trials, emphasize the importance of HER2 as the most
clinically relevant biomarker for selecting patients for
HER2-targeted therapy in the absence of signals for other
markers analyzed. The CLEOPATRA study also found
that although mutations in PIK3CA were not associatedwith resistance to pertuzumab, PIK3CA mutational status
may identify patients with poorer prognoses and particular
unmet medical needs suggesting that clinical trials of
HER2-targeted molecules in combination with PI3K
pathway-targeted agents may therefore be justified [11].
Additionally in the NeoSphere Study, pCR following
anti-HER2 antibody-based therapy was associated with
high expression of one or more of interferon gamma
(IFNγ), signal transducer and activator of transcription 1
(STAT1), major histocompatibility complex 2 (MHC2),
cluster of differentiation 8A (CD8A) and/or programmed
cell death-1 (PD1) [26], suggesting that adaptive immune
mechanisms might modulate the benefit from HER2-
directed therapy. Additional biomarker analyses from
ongoing studies such as NeoALTTO [27] may help to
detect further biomarkers to predict outcomes for
patients receiving HER2-targeted therapy in the neo-
adjuvant setting.
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http://breast-cancer-research.com/content/16/4/R73Currently, HER2 expression remains the only biomarker
for predicting outcomes for patients with HER2-positive
breast cancer and for basing treatment decisions on in the
clinic.
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